SMA Combination denied as not medically necessary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sma combination are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Combination SMA Therapy on Medical-Necessity Grounds

Spinal muscular atrophy (SMA) treatment has evolved rapidly, and BCBS — like most large commercial insurers — applies detailed medical-necessity criteria before approving combination therapy (typically two disease-modifying agents used together). Denials at this stage most often occur because the clinical record does not yet demonstrate, in the format the plan requires, that each agent is independently necessary and that combining them offers a clinically meaningful benefit the insurer has recognized.

## Why This Denial Is Appealable

SMA combination therapy is prescribed by leading neuromuscular specialists and is addressed in guidelines from professional organizations such as the Cure SMA–affiliated expert consortia and relevant neurology societies. If your physician has documented a clinical rationale grounded in your specific SMA type, functional baseline, prior treatment history, and current disease trajectory, that rationale forms the foundation of a strong appeal. A coverage denial is not a clinical determination — it is an administrative decision that must be re-examined when the full medical record is presented.

## Federal Appeal Framework

• Internal appeal (Level 1): Submit a written appeal with supporting clinical documentation. BCBS must issue a decision within the timeframe mandated by ACA and your plan documents.
• External review (ACA §2719 / state law): After exhausting internal appeals — or if BCBS issues a final adverse determination — you have the right to an independent external review by an accredited Independent Review Organization (IRO). The federal window for requesting external review is generally four months from the date of the adverse determination letter; confirm your specific deadline on that letter.
• Expedited review: If the standard timeline would seriously jeopardize your health, you may request an expedited internal appeal and simultaneous expedited external review. Decisions on expedited external reviews are typically required within 72 hours.
• ERISA plans: If coverage is through an employer self-funded plan, ERISA §503 guarantees a full-and-fair review with access to all evidence the plan relied on.

## Documentation to Gather

1. Confirmed diagnosis: Genetic testing report confirming SMA type and survival motor neuron (SMN) copy number. 2. Functional baseline: Recent standardized motor function assessments documented in the chart (e.g., scores on validated SMA-specific scales — ask your neurologist to include the most current assessment). 3. Prior treatment history: Dates, doses, and outcomes of each prior disease-modifying agent, including any documented plateau or functional decline. 4. Clinical severity narrative: Neurologist's detailed note on current progression, respiratory and swallowing status, and why monotherapy is insufficient. 5. Prescriber medical-necessity letter: A signed letter from the treating neuromuscular specialist stating the clinical rationale for combination therapy in terms of your specific case, referencing the FDA-approved labeling for each agent and the applicable professional society guidance.

## Criteria-Mapping Structure

Obtain the full text of BCBS's published medical policy for SMA combination therapy (request it from BCBS's member services or find it on their provider portal). For each requirement listed:

| Policy Requirement | Corresponding Chart Evidence | |---|---| | Confirmed genetic diagnosis | Genetic test report, date: ___ | | SMA type classification | Neurologist note, date: ___ | | Prior single-agent trial (specify agent and duration per policy) | Treatment records, dates: ___ to ___ | | Current functional status per validated scale | Assessment score, date: ___ | | Prescriber specialty requirement | Neuromuscular neurologist credentials |

Fill every row with exact chart facts before submitting. Blank rows are denial re-triggers.